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MINIMAL MORTALITY FROM VENO-OCCLUSIVE DISEASE FOLLOWING
BUSULFAN-BASED PREPARATIVE REGIMENS: A LARGE SINGLE INSTITU-
TION EXPERIENCE
Sproat, L., Bolwell, B., Rybicki, L., Kalaycio, M., Dean, R., Sobecks, R.,
Pohlman, B., Andresen, S., Sweetenham, J., Copelan, E. Cleveland Clinic
Taussig Cancer Institute, Cleveland, OH
Hepatic veno-occlusive disease (VOD) is a frequently cited life
threatening limitation of busulfan containing regimens. Reported
incidence ranges from 5% to .50% and mortality rates can be
substantial. Using a prospectively maintained database, a retrospec-
tive analysis was conducted to identify patients undergoing autolo-
gous or myeloablative allogeneic stem cell transplant with
busulfan/cyclophosphamide or busulfan/cyclophosphamide/etopo-
side as the preparative regimen at a single institution from 1993–
2007. The objective was to estimate the mortality from VOD.
1508 transplant patients (1037 autologous and 471 allogeneic)
were identified with 1 to 15 years of follow up. The autologous group
had VOD as the primary cause of death in only 3 patients (0.7% of
deaths, 0.3% total population). In this group the most common
cause of death was relapse (32% of total population, 74.9% of total
deaths). The cumulative incidence of non relapse mortality (NRM)
was 10.6% with respiratory failure (6.8%) being most common.
The allogeneic group had VOD as the primary cause of death in
only 8 patients (1.7% of total population, 2.4% of total deaths). In
this group the most common cause of death was relapse (22% of total
population, 31.1% of deaths). The cumulative incidence of NRM
was 47.8% with graft versus host disease (30.6%) being most com-
mon. Liver related mortality was not a significant factor in either
subset of patients. This is the largest single institution analysis on
the mortality risk of VOD following busulfan-based preparation.
Unlike some smaller previous reports, lethal VOD was infrequent
following busulfan-based preparation and not a significant cause of
mortality. When both autologous and allogeneic transplant groups
were combined, VOD was the primary cause of death in\1% of
patients. In conclusion, in a large single institution with significant
experience administering busulfan-based preparative regimens
for stem cell transplant VOD as a primary cause of death is extremely
low.289
DIFFERENTIAL MECHANISMS FOR CD41 AND CD81MEDIATED INFLAM-
MATION IN THE DEVELOPMENT OF EXPERIMENTAL IDIOPATHIC PNEU-
MONIA SYNDROME
Pierce, E.M.1, Hildebrandt, G.C.2, Askew, D.1, Eid, S.1, Jennings, A.1,
Cooke, K.R.1 1Case Western Reserve University, Cleveland, OH; 2Uni-
versity of Regensburg, Regensburg, Germany
Idiopathic pneumonia syndrome (IPS) is a frequently fatal compli-
cation following allogeneic BMT (allo-BMT). The pathophysiology
of IPS involves both soluble and cellular effectors. We examined the
role of cytolytic T lymphocyte (CTL) effector function in the devel-
opment of IPS using well-established murine BMT models. In initial
experiments, lethally irradiated B6D2F1 (F1) recipient mice re-
ceived BMT from either allogeneic (B6) or syngeneic (F1) donors.
Mice were then analyzed for the development of IPS and for donor
T cell chimerism, cytokine phenotype, and CTL activity in the lungs
at specified points after BMT. At week six, allo-BMT recipients de-
veloped significant lung injury compared to syngeneic controls. Do-
nor T cell chimerism in the lungs was complete by week 2 after
BMT, and RT-PCR analysis in combination with intra-cytoplasmic
staining and flow cytometry demonstrated that donor CD41 and
CD81 cells had a Th1/Tc1 phenotype; T cells expressed IFNg,
TNFa and RANTES but not IL-4 or IL-5. Furthermore, mRNA
expression revealed that lungs from allo-BMT recipients expressed
high levels of perforin, FasL and Fas within the first 2 weeks com-
pared to syngeneic controls. Immunohistochemistry and FACS
analysis confirmed that protein levels of Fas were also increased in
the lung after allo-BMT. Significant CTL activity (chromium re-
lease assay) mediated by both perforin and FasL was present as early
as week 2 after BMT. Next, F1 animals received allo-BMT from ei-
ther wild type (WT) B6 donors or from B6 mice deficient in either
perforin (pfp -/-) or FasL (gld). Recipients of gld, but not pfp -/-
BMT developed less IPS compared to allo-controls as characterized
by reductions in pathology, BAL fluid cellularity, numbers of bothdonor CD41 and CD81 T cells and TNFa levels. Further studies
using strain combinations wherein donor and host mice differed at
either MHC class I (CD81 mediated IPS) or MHC class II
(CD41mediated IPS), and additional donor mice lacking TNFa re-
vealed that CD41 cells use both FasL and TNFa whereas CD81T
cells appear to use TNFa exclusively during the evolution of IPS.
We conclude that CTL activity is present in the lungs of mice
with IPS and that differential pathways for cell-mediated cytolysis
are used by CD41 and CD81T cells in this setting. These data con-
firm a role for cellular effector mechanisms in IPS and may provide
insight toward developing novel strategies for treating this serious
complication of allo-BMT.290
PHASE I-II STUDY OF CLOFARABINE-MELPHALAN-ALEMTUZUMAB CON-
DITIONING FOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTA-
TION (HCT) IN PATIENTS WITH ADVANCED HEMATOLOGIC
MALIGNANCIES: UNEXPECTED RENAL TOXICITY
van Besien, K., Kline, J., Godley, L., Larson, R.A., Odenike, O.,
Rich, E.S., Stock, W., Wickrema, A., Swanson, K., Horowitz, S., Del
Cerro, P., Schroeder, L., Pape, L., Allen, S., Artz, A.S. University of Chi-
cago, Chicago, IL
Fludarabine Melphalan-alemtuzumab (Flu-Mel-Camp) condi-
tioning has high recurrence rates . Clofarabine (Clo), a second gen-
eration nucleoside analog, might enhance disease control. We report
an ongoing phase I-II study of Clo-Mel-Camp conditioning. GVHD
prophylaxis used tacrolimus. For the phase I, one pt was enrolled per
level, until the first DLT or until 2 had gr 3 toxicity. Level 1 was: Clo
10 mg/m2/day on d -7 to -3 and Mel 100 mg/m2 on day -2. Clo was
increased by 10 mg per cohort until 40 mg/m2/d. Then Mel by 20
mg until 140 mg/m2. 12 pts were accrued in the phase I. 4 died
from TRM: 2 of early sepsis unrelated to Clo toxicity; 1 from
multi-organ failure and possible regimen related toxicity (RRT);
and 1at d159 from sepsis. The phase II dose was Clo 40 mg/m2/
day x 5 d and Mel 140 mg/m2. 3 pts in the phase I and 21 pts in
the phase II portion received this dose. Median age 53 (20–70); 17
Myeloid, 1 CLL, 15 NHL; 26 high or intermediate risk. 5 relapse
after alloHCT, 7 after auto HCT. HCT-CI was . 5 3 in 12 and
ECOG PS . 5 1 in 13. 18 had sib and 15 MUD donors. All evalu-
able pts engrafted. Median d 30 donor chimerism was 95% (14–100)
with no late graft failures. There were 3 deaths from TRM in the
phase II: 2 from RRT and 1 from GVHD. Grade 3–4 renal toxicity
occurred between day -7 and day 17 in 4 of 24 (17%) pts receiving
full dose Clo and Mel. Only1 has recovered. No grade 3 renal
toxicity occurred between day -7 and day 17 among 112 pts on
Flu-Mel-Camp(p \ 0.000). In addition grade 2 renal failure
occurred in 8 pts, reversible in 5. Other toxicities included: gr 2–3
reversible ALT elevation in 17 pts; gr 2 reversible bilirubin elevation
in 2 pts; gr 2–3 hand-foot syndrome in 10 pts; gr 3 mucositis and pul-
monary hemorrhage in 1 pt; With median follow-up of 175 days (12–
487), 3 of 12 in the phase I, and 16 of 21 pts in the phase II portion
remain in remission. Estimated day 180 progression-free survival is
53% (95% CI: 34–72) with no failures beyond day 160.
Conclusions: Clo-Mel-Camp induces durable engraftment.
Response and duration of response are encouraging. Common tox-
icities are elevation of transaminases, hand foot syndrome and grade
2–4 renal failure. There were seven TRM, all in pts with high risk
disease, prior transplant and/or multiple comorbidities. Three
TRM were attributed to Clo toxicity and occurred in the context
of early onset grade 3–4 renal failure. Because of this, the Clo dose
will be reduced to 30 mg/m2/day x 5 days.291
TOTAL MARROW AND LYMPH NODE IRRADIATION (TMLI) WITH
FLUDARABINE (FLU) AND MELPHALAN (MEL) IS WELL TOLERATED
AND MAY RESULT IN IMPROVED OUTCOME IN PATIENTS (PTS) WITH
ADVANCED HEMATOLOGICAL MALIGNANCIES
Rosenthal, J.1, Wong, J.2, Stein, A.1, Naeem, H.3, Hitt, D.1, Forman, S.1
1City of Hope, Duarte, CA; 2City of Hope; 3City of Hope
Reduced intensity conditioning (RIC) with FLU/MEL followed
by hematopoietic stem cell transplantation (HSCT) may result in
106 Poster Session-IIlong-term survival in pts with hematologic malignancies and com-
promised organ function (COF); however, pts with advanced disease
do poorly with RIC alone (Giralt, Biol. Blood Marrow Transplant,
13:884, 2007). In an attempt to improve the anti-tumor efficacy of
RIC, while maintaining a low-toxicity profile, we added TMLI to
FLU/MEL. We hypothesize that Flu/Mel with 1200 cGY of
TMLI delivered using Tomotherapy Hi-Art system is safe, tolerable,
and may improve outcome in pts with COF and advanced hemato-
logical malignancies.
Patients and Methods: Pts, $50 years of age or COF with
advanced disease status defned as high-risk remission and marrow
blasts #10%, were eligible. The RIC consisted of FLU 25 mg/m2/
d x 5 days, MEL 140 mg/m2 for one day, and TMLI delivered at
150 cGy/fraction in 8 fractions over 4 days.
Results: There were 16 evaluable pts (median age: 50.8 yr range
24.3–65.7 yr). The diagnoses were: AML (n 5 10), ALL (n 5 3),
NHL (n 5 2), multiple myeloma (n 5 1),. At the time of HSCT 9
patients (56%) had advanced disease: 1st or 2nd relapse (n5 3), induc-
tion failure (n5 5) and progressive disease (n5 1). Seven pts (44%)
were in complete remission. Mobilized peripheral blood stem cells
from HLA-identical siblings (n 5 7) or matched unrelated donor
(n 5 9) were used in all cases. Transplant-related toxicities by day
130 included: nausea grade 2 (n5 4) grade 3 (n5 12), emesis grade
2 (n5 6) and grade 3 (n5 4), mucositis grade 2 (n5 2) and grade 3
(n 5 14) and fatigue grade 2 (n 5 6) grade 3 (n 5 4). Myeloid and
platelet engraftment occurred at a median of 15 (range: 10–19
days) and 16 (range:10–19 days) days post transplant, respectively.
Acute GvHD grade II-IV occurred in 38.5% of patients (grade II
(31%) and grade III in 7.5%) and extensive chronic GVHD in 3
patients (19%). Five patients expired; 2 of relapsed disease, 1 with
a secondary malignancy, and 2 of transplant related mortality. At
a median of 12 month overall survival (OS) and disease-free survival
(DFS) are 81% (95% CI, 51%–93%), and 59% (95% CI,
23%–82%), respectively.
Conclusion: The addition of TMLI at a dose to RIC with FLU/
MEL appears to be tolerable and safe. The low rate of relapse and
improved OS and DFS compared to historical data are promising.
A study is ongoing to further assess efficacy in pts with hematological
malignancies who are not eligible for RIC due to disease burden.
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CYCLOSPORINE, MYCOPHENOLATE MOFETIL AND METHOTREXATE AS
POST GRAFTING IMMUNOSUPPRESSION AFTER NONMYELOABLATIVE
ALLOGENEIC STEM CELL TRANSPLANTATIONS CONDITIONED WITH
FLUDARABINE AND LOW-DOSE TOTAL BODY IRRADIATION
Poon, M.L.M., Tan, L.K., Tan, B., Lee, Y.M., Liu, T.C., Ng, C.H.,
Lee, S.Y., Soh, T.G., Nur, S., Koh, L.P. National University Hospital,
Singapore, Singapore
Introduction: Nonmyeloablative (NM) hematopoietic cell trans-
plantation (HCT) has extended the potential curative treatment
option of allografting to patients in whom it was previously contrain-
dicated due to advanced age or comorbidity. Graft-versus-host
disease (GvHD), however, remains one of the major impediments
to long term remission. Recently, our group has introduced a modi-
fied post grafting immunosuppression by adding methotrexate
(MTX) onto the standard mycophenolate mofetil (MMF)/cyclo-
sporin (CsP) for NMHCT recipients., with significant reduction in
severe GvHD and non relapse mortality (NRM), thereby conferring
favorable survival in patients receiving NMHCT. The current study
is initiated to assess the feasibility and efficacy of similar approach in
the setting of single institution with additional patient accrual.
Patients and Methods: Twenty-seven patients (median age, 47
years) with hematological diseases, who were poor candidates for
a conventional myeloablative transplantation, receiving NM condi-
tioning with fludarabine 90 mg/m2 and total body irradiation
(TBI) 200-cGy, followed by filgrastim-mobilized peripheral blood
stem cell transplant from HLA identical (n5 26), or matched unre-
lated (n 5 1) donors. Diagnosis include leukemia/MDS (n 5 17),
lymphoma (n 5 2), ALL (n 5 1), myeloma (n 5 5) and CML (n 5
2). All patients were given CSP, MMF and short course of MTX
as post-grafting immunosuppression.
Results: The median times to neutrophil (500/mL) and platelet
recovery (20,000/mL) were 20 and 13 days, respectively. Myelosup-
pression was moderate with neutrophil counts not declining below
500/mL in 5 (19%) patients, and with more than half of the patientsnot requiring any blood or platelet transfusion. Non-relapse mortal-
ity was low with no transplant related death occurring within the first
1 year. Overall, 11 (20%) patients had grade 2–4 acute GvHD, with
only 5 (9%) patients experiencing grade 3–4 acute GVHD. Acute
GVHD was diagnosed at median day 198 (range, days 133 to
1158). Extensive chronic GVHD was observed in 2 of 24 evaluable
patients (8.3%). Relapse-related death occurred in 6 (11%) patients.
At median follow-up of 40 months (range, 20–57 months), the 4-year
probability of overall and progression-free survival were 61% and
42%, respectively.
Conclusions: The addition of MTX onto the CSP and MMF as
post grafting immunosuppresion offers the possibility of further
optimization of GvHD control in patients receiving NMHCT,
with encouraging survival.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) FOR PA-
TIENTS IN THE 6TH AND 7TH DECADES OF LIFE WITH AML OR MDS US-
ING MYELOABLATIVE, REDUCED TOXICITY IV BUSULFAN/FLUDARABINE
(BUFLU) CONDITIONING REGIMEN
Alatrash, G.1, Andersson, B.1, Pelosini,M.2, Rondon, G.1, Qazilbash,M.1,
Giralt, S.1, de Padua Silva, L.1, Hosing, C.1, Kebriaei, P.1, Zhang, W.1,
Saliba, R.1, Champlin, R.1, de Lima, M.1 1UT MD Anderson Cancer
Center, Houston, TX; 2University of Pisa, Pisa, Italy
AML and MDS are moderately sensitive to the graft-versus leuke-
mia effect, therefore making the preparative regimen dose intensity
an important part of the treatment plan. For patients older than
age 55, the optimal conditioning regimen prior to HSCT remains
to be determined. Because of the high rates of morbidity and mortal-
ity associated with HSCT in the elderly, many patients older than
50–55 years are excluded from treatment with myeloablative condi-
tioning regimens. Herein, we report promising findings using intra-
venous (IV) BuFlu myeloablative conditioning regimen in patients
older than age 54 years with AML or MDS.
Methods: A cohort of 74 patients age 55 years with AML (n5 60)
with high or intermediate risk cytogenetics or MDS (n 5 14) with
a high IPSS were transplanted in first complete remission (CR1) or
with disease beyond CR1. The preparative regimen consisted of
IV Flu 40 mg/m2 and IV Bu 130 mg/m2 given once daily over 3
hours on pre-transplant days -6 to -3. Graft-versus-host disease
(GVHD) prophylaxis was accomplished with use of Tacrolimus
and methotrexate.
Results: Median age was 58 years (range 55–66); 18 patients
(24%) were older than 59 years. Fifty-four percent of patients were
in complete remission (CR); 32% in first CR (CR1) and 22% in
second CR (CR2); 46% had active disease. Donors were HLA-
matched related (50%) and unrelated (50%). All patients engrafted.
Forty-one percent and 7% of the patients had grades II-IV and
III-IV acute GVHD, respectively. Chronic GVHD rate was 42%.
Median follow-up is 22 months (range 1–82 months). Two-year
overall survival (OS) was 70%, 48%, and 35% for patients trans-
planted in CR1, CR2, and with active disease, respectively. For
patients in CR1, CR2, and with active disease at time of HSCT,
actuarial 2-year event free survival (EFS) is 65%, 45%, and 30%, re-
spectively. Thirty-two percent of the patients have relapsed (n5 24).
Disease progression (n5 22), GVHD (n5 8), infection (n5 3), and
organ failure (n 5 3) were the primary causes of death. TRM and
survival are shown in Table.
Conclusion:Our results show low TRM rates for selected patients
in the 6th and 7th decades of life with high-risk AML and MDS who
received BuFlu. Furthermore, long-term follow up indicates that
responses with this regimen are stable in a significant proportion of
patients. We conclude that age in itself should not be the primary
reason to exclude patients from receiving myeloablative transplants.Cumulative Incidence of Transplant-Related Mortality (TRM)
by Pre-Transplant Disease Status
TRM 30-Days 100-Days 1-yearAll patients None 4% 21%
All CR (n540) None 5% 18%
CR1 (n524) None 4% 15%
Persistent Disease (n534) None 3% 27%
